HomeComparePGPEF vs ABBV

PGPEF vs ABBV: Dividend Comparison 2026

PGPEF yields 5.18% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PGPEF wins by $7500.72M in total portfolio value
10 years
PGPEF
PGPEF
● Live price
5.18%
Share price
$82.05
Annual div
$4.25
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7500.82M
Annual income
$7,232,491,209.75
Full PGPEF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PGPEF vs ABBV

📍 PGPEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPGPEFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PGPEF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PGPEF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PGPEF
Annual income on $10K today (after 15% tax)
$440.13/yr
After 10yr DRIP, annual income (after tax)
$6,147,617,528.29/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PGPEF beats the other by $6,147,596,472.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PGPEF + ABBV for your $10,000?

PGPEF: 50%ABBV: 50%
100% ABBV50/50100% PGPEF
Portfolio after 10yr
$3750.46M
Annual income
$3,616,257,990.75/yr
Blended yield
96.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PGPEF
No analyst data
Altman Z
1.6
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PGPEF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPGPEFABBV
Forward yield5.18%3.06%
Annual dividend / share$4.25$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$7500.82M$102.3K
Annual income after 10y$7,232,491,209.75$24,771.77
Total dividends collected$7482.04M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PGPEF vs ABBV ($10,000, DRIP)

YearPGPEF PortfolioPGPEF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,736$1,035.60$11,550$430.00+$186.00PGPEF
2$14,829$2,271.66$13,472$627.96+$1.4KPGPEF
3$21,232$5,365.23$15,906$926.08+$5.3KPGPEF
4$37,077$14,358.87$19,071$1,382.55+$18.0KPGPEF
5$86,541$46,868.57$23,302$2,095.81+$63.2KPGPEF
6$297,076$204,476.98$29,150$3,237.93+$267.9KPGPEF
7$1,629,877$1,312,006.14$37,536$5,121.41+$1.59MPGPEF
8$15,198,531$13,454,562.40$50,079$8,338.38+$15.15MPGPEF
9$250,773,032$234,510,603.65$69,753$14,065.80+$250.70MPGPEF
10$7,500,818,354$7,232,491,209.75$102,337$24,771.77+$7500.72MPGPEF

PGPEF vs ABBV: Complete Analysis 2026

PGPEFStock

Publicis Groupe S.A. provides marketing, communications, and digital business transformation services in North America, Europe, the Asia Pacific, Latin America, Africa, and the Middle East. The company offers advisory services for brand strategy, and repositioning and their identity under the Publicis Worldwide, Saatchi & Saatchi, Leo Burnett, Marcel, Fallon, and BBH brands; online advertising services under the Razorfish and Moxie brand names; crisis communications, media relations, public affairs, financial communications, and strategy and event management services; media consulting, planning, and buying services; performance marketing services; and e-commerce services to optimize distribution channels. It also designs and delivers brand content for various channels, such as television, print, radio, cinema, and billboards, as well as digital, including display, social networks, Internet video, etc. under the Prodigious, Harbor, and The Pub brand names. In addition, the company operates Epsilon PeopleCloud, a unified data and technology platform; and Publicis Sapient, a technological, digital, and consulting platform for automotive, consumer products, energy and raw materials, retail, financial services, healthcare, media-telecoms, and travel and hospitality sectors. Further, it provides healthcare communication services under the Digitas Health, Publicis Health Media, and Saatchi & Saatchi Wellness brands for the healthcare and well-being sectors. The company serves clients in the non-food consumer products, finance, automotive, TMT, healthcare, food and beverage, leisure and travel, energy and industry, retail, and public and other sectors. Publicis Groupe S.A. was founded in 1926 and is headquartered in Paris, France.

Full PGPEF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PGPEF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PGPEF vs SCHDPGPEF vs JEPIPGPEF vs OPGPEF vs KOPGPEF vs MAINPGPEF vs JNJPGPEF vs MRKPGPEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.